Ophthalmic drug delivery system and method

Patent metadata

Field	Value
Publication number	US-9486357-B2
Application number	US-201213457568-A
Country	US
Kind code	B2
Filing date	Apr 27, 2012
Priority date	Nov 13, 2008
Publication date	Nov 8, 2016
Grant date	Nov 8, 2016

Abstract

A method to provide a therapeutic agent to an eye of a patient by implanting or inject a device that stably fits a particular location or position in the eye. The method thus provides agent inside the eye for a longer duration of agent release over a space-occupying area inside the eye.

First claim

What is claimed is:

1. A method of providing a therapeutic agent to an eye of a patient, the method comprising
providing to an eye of the patient a device that is 15 mm to 60 mm in length, deformable, biodegradable and absorbable and containing at least one of:
(i) a therapeutic agent selected from the group consisting of a rho kinase inhibitor, a platelet-derived growth factor inhibitor, and an integrin inhibitor; and
(ii) stem cells released upon injecting in the patient's eye, a releasable neuronal cell protective agent and optionally other agents, the device shaped to stably fit a superchoroidal or subretinal position in the eye choroid or on the lens zonules, and sized to occupy the choroidal space inside the eye or the space on the lens zonules to provide a relatively longer duration of agent release over a relatively larger space-occupying area inside the eye; and
implanting the device suprachoroidially between the sclera and the choroid posteriorly with respect to the pars plana of the eye or subretinally following the curvature of the retina and subretinal space but not bulging the retina.

2. The method of claim 1 further comprising implanting the device suprachoroidially in the suprachoroidal space and the agent is contained in and/or on or with the device delivered to the choroid and retina.

3. The method of claim 1 further comprising implanting the device subretinally in the subretinal space and the agent is contained in and/or on or with the device delivered to the sensory retina.

4. The method of claim 1 where the patient has an ocular disease.

5. The method of claim 1 performed during ocular surgery.

6. The method of claim 1 performed after ocular surgery to prevent ocular inflammation.

7. The method of claim 1 where the neuronal cell protective therapeutic agent is a rho kinase inhibitor.

8. The method of claim 1 where the device is provided by an incision as small as 1 mm.

9. The method of claim 1 providing the device with forceps.

10. The method of claim 1 where the device is provided by injecting the device.

11. The method of claim 1 where the device is provided by folding the device for providing the device to the eye, then unfolding the device once the device is in the eye.

12. The method of claim 1 where the device further includes additional other therapeutic agents selected from the group consisting of a vascular endothelial growth factor inhibitor, a platelet derived growth factor inhibitor, an integrin inhibitor, and combinations thereof.

13. The method of claim 1 where the patient has a retinal degenerative disease.

14. The method of claim 1 where the device has one of the following shapes: (i) a rod shape, (ii) a tube shape, (iii) snake-shaped semicircle, or an (iv) open loop shape, but not a closed loop shape.

15. The method of claim 1 where the device has semicircle shape, but not a circular shape.

16. A method of providing a therapeutic agent to an eye of a patient, the method comprising providing to an eye of the patient a device that is 15 mm to 60 mm in length, deformable, biodegradable and absorbable and containing at least one of: (i) a therapeutic agent selected from the group consisting of a rho kinase inhibitor, a platelet-derived growth factor inhibitor, and an integrin inhibitor; and (ii) stem cells released upon injecting in the patient's eye, the device shaped to stably fit a position on the lens zonules, and sized to occupy a space inside the eye to provide a longer duration of agent release over a space-occupying area inside the eye; and
implanting the device over the lens capsule and between the iris and the lens in the posterior chamber.

17. The method of claim 16 where the device is C-shaped or ring shaped.

18. The method of claim 16 where the therapeutic agent is a rho kinase inhibitor.

19. The method of claim 16 where the device is provided by an incision as small as 1 mm.

20. The method of claim 16 where the device is provided by folding the device for providing the device to the eye, then unfolding the device once the device is in the eye.

21. The method of claim 1 further comprising implanting the device containing agents that are neuronal cell protective and/or neuronal cell proliferative for therapy to the patient having or having a genetic predisposition to a neurodegenerative disease selected from the group consisting of a dry form of age related macular degeneration (ARMD), a wet form of ARMD, retinitis pigmentosa, diabetic retinopathy, and combinations thereof.

Assignees

• Peyman Gholam A

Inventors

• Peyman Gholam A

Classifications

• A61K31/436

  the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin · CPC title

• A61K9/0051

  Ocular inserts or implants · CPC title

• A61F9/0017 Primary

  implantable in, or in contact with, the eye, e.g. ocular inserts · CPC title

• A61K38/13

  Cyclosporins · CPC title

• A61P27/02

  Ophthalmic agents · CPC title